Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Noninfectious...

To compare 5-year systemic complication risks in noninfectious uveitis (NIU) patients treated with systemic biologic versus conventional therapy.

Multicenter, retrospective clinical cohort study.

Adult patients (≥18 years old) with NIU from the TriNetX Collaborative Network.

We identified patients with NIU. We assembled propensity score-matched comparisons: biologic therapy versus no systemic therapy (n = 6896 each) and biologic versus conventional therapy with corticosteroids matched (n = 5994 each) between January 1, 2005, and January 1, 2024. A prespecified subgroup analysis of Analysis 2 restricted to patients receiving combination biologic + conventional therapy versus conventional therapy alone (n = 3653 each) was also conducted. We used time-to-event analyses to identify incidence of systemic complications.

Incidence of serious infections, hematologic cytopenias, heart failure, thromboembolic events, diabetes mellitus, malignancy, psychiatric illness, all-cause hospitalization, and all-cause mortality.

After propensity score matching, cohorts were balanced on all measured covariates (all standardized mean differences [SMDs] <0.1). Compared with no systemic therapy, biologic treatment was associated with higher 5-year risks of serious infections, including pneumonia (hazard ratio [HR], 1.41, 95% confidence interval [CI], 1.20-1.67), sepsis (HR, 1.43, 95% CI, 1.16-1.77), and hematologic cytopenias (HR, 1.58, 95% CI, 1.44-1.74), representing 5-year Kaplan-Meier-estimated cumulative incidences of 6.43%, 3.87%, and 30.12%, respectively, in biologic-treated patients. Risks of heart failure, thromboembolic events, psychiatric illness, diabetes, and all-cause mortality did not significantly differ between groups. When compared with conventional immunomodulatory therapy, biologic treatment demonstrated a largely comparable 5-year safety profile, with the primary exceptions of higher rates of hematologic cytopenias (HR, 1.28, 95% CI, 1.16-1.41), psychiatric illness (HR, 1.13, 95% CI, 1.01-1.27), and hospitalization (HR, 1.20, 95% CI, 1.07-1.35).

In patients with NIU, systemic biologic therapy was associated with higher risks of serious infections and hematologic cytopenias compared with no systemic treatment, while demonstrating a 5-year safety profile broadly comparable to conventional immunomodulatory therapy. These findings support guideline-concordant stepwise immunosuppression and underscore the importance of individualized risk assessment, infection surveillance, and hematologic monitoring for patients requiring systemic therapy.

Proprietary or commercial disclosure may be found after the references.